Cancer Research Grants  Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 68, 5397, July 1, 2008. doi: 10.1158/0008-5472.CAN-07-6792
© 2008 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zeng, B.
Right arrow Articles by Yang, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zeng, B.
Right arrow Articles by Yang, R.

Immunology

Tumor-Induced Suppressor of Cytokine Signaling 3 Inhibits Toll-like Receptor 3 Signaling in Dendritic Cells via Binding to Tyrosine Kinase 2

Bin Zeng, Haijie Li, Yu Liu, Zhuohan Zhang, Yuan Zhang and Rongcun Yang

Department of Immunology, Nankai University School of Medicine, Nankai University, Tianjin, People's Republic of China

Requests for reprints: Rongcun Yang, Department of Immunology, Nankai University School of Medicine, 94 Weijin Road, Tianjin 300071, People's Republic of China. Phone: 86-22-23509007; Fax: 86-22-23502554; E-mail: ryang{at}nankai.edu.cn.

Key Words: SOCS3 • TYK2 • Dendritic cells • IFN{alpha}

The suppressor of cytokine signaling (SOCS) family of negative regulatory proteins is up-regulated in response to several cytokines and pathogen-associated molecular patterns (PAMP) and suppresses cellular signaling responses by binding receptor phosphotyrosine residues. Exposure of bone marrow–derived dendritic cells (BMDC) to 1D8 cells, a murine model of ovarian carcinoma, suppresses their ability to express CD40 and stimulate antigen-specific responses in response to PAMPs and, in particular, to polyinosinic acid:poly-CMP (polyI:C) with the up-regulated SOCS3 transcript and protein levels. The ectopic expression of SOCS3 in both the macrophage cell line RAW264.7 and BMDCs decreased signaling in response to both polyI:C and IFN{alpha}. Further, knockdown of SOCS3 transcripts significantly enhanced the responses of RAW264.7 and BMDCs to both polyI:C and IFN{alpha}. Immunoprecipitation and pull-down studies show that SOCS3 binds to the IFN{alpha} receptor tyrosine kinase 2 (TYK2). Because polyI:C triggers autocrine IFN{alpha} signaling, binding of SOCS3 to TYK2 may thereby suppress the activation of BMDCs by polyI:C and IFN{alpha}. Thus, elevated levels of SOCS3 in tumor-associated DCs may potentially resist the signals induced by Toll-like receptor 3 ligands and type I IFN to decrease DC activation via binding with IFN{alpha} receptor TYK2. [Cancer Res 2008;68(13):5397–404]




This article has been cited by other articles:


Home page
Cancer Res.Home page
Z. Zhang, B. Zeng, Z. Zhang, G. Jiao, H. Li, Z. Jing, J. Ouyang, X. Yuan, L. Chai, Y. Che, et al.
Suppressor of Cytokine Signaling 3 Promotes Bone Marrow Cells to Differentiate into CD8+ T Lymphocytes in Lung Tissue via Up-Regulating Notch1 Expression
Cancer Res., February 15, 2009; 69(4): 1578 - 1586.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2008 by the American Association for Cancer Research.